BioWorld

Feb. 11, 2010

Alexza Brings in $40M from Biovail Deal to Develop Inhaled Antipsychotic

Alexza Pharmaceuticals Inc. and Biovail Laboratories International SRL have agreed to develop and commercialize Alexza's inhaled antipsychotic AZ-004 (Staccato loxapine) in the U.S. and Canada in a deal worth $130 million. (BioWorld Today) Read More

Mipomersen a Niche-Only Drug? Safety Drags Positive Phase III

Lysosomal Storage Disorder Gene Implicated in Stuttering

Daring 'TB' Different; Early Stage Aarden Working on PTP Drugs

Clinic Roundup

Other News To Note

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 17, 2025.

Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA

BioWorld

During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...

23andme founder-led group outbids Regeneron for company

BioWorld

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...

Elevidys’ second liver death hits Sarepta, sends DMD ripples

BioWorld

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...